Niagen Bioscience, Inc.
Niagen Bioscience, Inc. (Nasdaq: NAGE) is a bioscience company focused on NAD+ research and products intended to support healthy aging. Its principal ingredient is Niagen®, a form of nicotinamide riboside chloride, sold as a food-grade ingredient and in pharmaceutical grade for compounding into prescription… From the company’s description.
Over the twelve months to Sep 30, 2026, Niagen Bioscience, Inc. reported revenue of $122.29M, down 1.9% from a year earlier, and net income of $10.24M. Its operating margin was 3.9%, and operations generated $4.88M in cash. In fiscal 2025, it reported revenue of $129.42M, up 29.9% from fiscal 2024, and net income of $17.38M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Niagen Bioscience, Inc. does
In the company’s own words
Niagen Bioscience, Inc. (Nasdaq: NAGE) is a bioscience company focused on NAD+ research and products intended to support healthy aging. Its principal ingredient is Niagen®, a form of nicotinamide riboside chloride, sold as a food-grade ingredient and in pharmaceutical grade for compounding into prescription intravenous and injectable formulations. The company sells finished dietary supplements under its Tru Niagen® brand directly to consumers and through online marketplaces, retailers, practitioners and international distribution partners; ingredient customers include consumer-product manufacturers and outsourcing facilities. Its segments include Consumer Products, Ingredients, and Pharmaceutical, which conducts research and development for potential therapeutic applications; the analytical reference standards and services business was sold under an agreement signed in February 2026. In 2025, Consumer Products generated $97.7 million and Ingredients generated $28.7 million of the company’s $129.4 million in net sales, while Pharmaceutical generated no revenue. Niagen Bioscience reported 117 full-time employees as of December 31, 2025. Its website is www.niagenbioscience.com.
Company details
- Sector
- Consumer Staples
- Industry (SIC)
- Chemicals
- Headquarters
- LOS ANGELES, CA
- Fiscal year end
- December
- CIK
- 1386570
- SIC
- 2833
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Niagen Bioscience, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Niagen Bioscience, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Niagen Bioscience, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Niagen Bioscience, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Niagen Bioscience, Inc.'s last four quarterly filings that the numbers alone won't show?”